๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS ยท Real-Time Price ยท USD
3.300
-0.080 (-2.37%)
Nov 18, 2026, 10:41 AM EST - Market open

Aclaris Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
6.47.8318.7231.2529.756.76
Revenue Growth
-59.34%-58.19%-40.09%5.03%340.05%4.30%
Gross Profit
-66-52.1-30.32-83-60.02-41.77
Operating Income
-90.41-74.08-52.53-114.51-85.15-65.38
Net Income
-79.63-64.92-132.07-88.48-86.91-90.87
Earnings Per Share
-0.59-0.53-1.71-1.27-1.33-1.60
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
204.61151.36203.9181.88229.81225.66
Total Debt
1.712.122.63.52.252.89
Net Cash (Debt)
202.9149.25201.3178.38227.56222.76
Net Cash Growth
22.99%-25.86%12.85%-21.61%2.15%457.17%
Net Cash Per Share
1.491.222.602.563.493.93

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-75.21-47.11-20.08-78.33-67.57-52.13
Capital Expenditures
-0.11-0.11-0.12-1.31-0.61-0.31
Free Cash Flow
-75.32-47.22-20.2-79.63-68.17-52.44
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
---161.99%-265.60%-201.74%-
Operating Margin
-1412.40%-946.52%-280.59%-366.44%-286.21%-967.08%
Pretax Margin
-1244.09%-829.58%-705.48%-284.32%-292.11%-1343.96%
Profit Margin
-1244.09%-829.58%-705.48%-283.15%-292.11%-1343.96%
FCF Margin
-1176.61%-603.42%-107.89%-254.84%-229.13%-775.65%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
83.7541.6714.182.3835.30131.67